Correlation Between Esperion Therapeutics and Supernus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Esperion Therapeutics and Supernus Pharmaceuticals, you can compare the effects of market volatilities on Esperion Therapeutics and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Supernus Pharmaceuticals.

Diversification Opportunities for Esperion Therapeutics and Supernus Pharmaceuticals

0.68

Correlation Coefficient

Esperion Therapeutics  Supernus Pharmaceuticals

Poor diversification

The 3 months correlation between Esperion and Supernus is 0.68. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Supernus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and Supernus Pharmaceuticals

Given the investment horizon of 90 days Esperion Therapeutics is expected to under-perform the Supernus Pharmaceuticals. In addition to that, Esperion Therapeutics is 1.33 times more volatile than Supernus Pharmaceuticals. It trades about -0.12 of its total potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about -0.07 per unit of volatility. If you would invest  3,691  in Supernus Pharmaceuticals on December 29, 2024 and sell it today you would lose (462.00) from holding Supernus Pharmaceuticals or give up 12.52% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Esperion Therapeutics  vs.  Supernus Pharmaceuticals

Esperion Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Supernus Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Supernus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest inconsistent performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Esperion Therapeutics and Supernus Pharmaceuticals

The main advantage of trading using opposite Esperion Therapeutics and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.

The idea behind Esperion Therapeutics and Supernus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.